Because the TCGA-BRCA dataset lacked information on ICIs treatment, we used two IPS-valued subtypes (IPS- PD-L1/PD-1/PD-L2 blocker and IPS-CTLA-4 blocker) as proxies for response to anti-PD-1/PD-L1 and anti-CTLA-4 treatment in BC patients. The gene discussed is CTLA4; the disease is breast cancer.